CASI Pharma gets NMPA’s nod to conduct confirmatory trial of ZEVALIN®
Category: #health  By Mateen Dalal  Date: 2019-02-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

CASI Pharma gets NMPA’s nod to conduct confirmatory trial of ZEVALIN®
  • The firm previously secured greater China rights to ZEVALIN® from Spectrum and aims to launch ZEVALIN® in the country.
  • CASI Pharmaceuticals is currently addressing certain stipulations prescribed by the Center for Drug Evaluation (CDE) – a part of the NMPA

The U.S. based CASI Pharmaceuticals, Inc. has reportedly secured the approval from China’s National Medical Products Administration (NMPA) for its Clinical Trial Application (CTA) which allows it to conduct a confirmatory clinical trial, evaluating the safety and efficacy of ibritumomab tiuxetan injection (ZEVALIN®).

As per trusted sources, Ibritumomab tiuxetan (ZEVALIN®) is presently marketed in the U.S. by Spectrum Pharmaceuticals, Inc. For the record, ZEVALIN® is a U.S. FDA-approved drug indicated for the treatment of patients suffering from relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma.

ZEVALIN® is augmented with a beta-emitting radioisotope and primarily builds on the combined therapeutic effects of a monoclonal antibody targeted against the CD20 antigen.

According to a press release issued by CASI Pharmaceuticals, the firm has previously secured greater China rights to ZEVALIN® from Spectrum Pharmaceuticals and aims to introduce the drug in the nation as soon as the confirmatory trial is concluded and marketing approval is secured from the NMPA.

The Executive Chairman of CASI Pharmaceuticals, Wei-Wu He, Ph.D., was reportedly quoted saying that the company is delighted to receive the approval from NMPA as now it can commence the confirmatory clinical trial for ZEVALIN® in China. The approval is a significant breakthrough for CASI Pharmaceuticals given the fact that it characterizes the regulatory strength of the firm’s team in working closely with the NMPA and the effective cross-border operations of the teams in China and the United States, Wei-Wu He further added.

Sources familiar with the development claim that CASI Pharmaceuticals is currently addressing certain stipulations laid down by the Center for Drug Evaluation (CDE), a part of the NMPA. The firm would be allowed to commence the ZEVALIN® clinical development program in China after satisfying those requirements.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Stocks of luxury fashion houses raise in response to China’s reopening
Stocks of luxury fashion houses raise in response to China’s reopening
By Mateen Dalal

Luxury fashion houses dependent on Chinese customers reportedly saw a hike in stocks as China reopens, however, those clients may not necessarily be purchasing the goods elsewhere. In the past, wealthy Chinese customers would frequently buy person...

Microsoft investigates Teams and Outlook outage that left users disrupted
Microsoft investigates Teams and Outlook outage that left users disrupted
By Mateen Dalal

Microsoft, the U.S.-based technology frontrunner, reportedly investigating an outage that prevented thousands of customers from accessing services like Teams and Outlook. Apparently, the tech giant did not disclose the number of users that were im...

DeHaat secures $60 million in funding, tops $700 million valuation
DeHaat secures $60 million in funding, tops $700 million valuation
By Mateen Dalal

Indian agritech firm DeHaat has reportedly raised $60 million in a new funding round as it looks forward to strengthening its footprint in the country and touching break-even profitability in two years. For the unversed, the startup provides a range ...